Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 -7.44%72 PEG Ratio is 0.78 as of Aug. 03, 2026, which is 58% below its 10-year median of 1.85. GuruFocus rates BOM:531762 with a GF Score™ of 72/100 and a GF Value™ of ₹23.17 (Modestly Overvalued). Among 351 Drug Manufacturers companies, Unjha Formulations ranks better than 78.92% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Unjha Formulations's PEG Ratio or its related term are showing as below:
BOM:531762'
s PEG Ratio Range Over the Past 10 Years
Min: 0.69 Med: 1.85 Max: 26.36
Current: 0.76
During the past 13 years, Unjha Formulations's highest PEG Ratio was 26.36. The lowest was 0.69. And the median was 1.85.
BOM:531762's PEG Ratio is ranked better than 78.92% of 351
companies
in the Drug Manufacturers industry
Industry Median: 1.72
vs BOM:531762: 0.76
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Unjha Formulations (BOM:531762) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Unjha Formulations PEG Ratio Related Terms
Unjha Formulations PEG Ratio Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Unjha Formulations (BOM:531762) has a PEG Ratio of 0.78 as of Aug. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Unjha Formulations and its competitors. This is 58% below median its historical median of 1.85. Over the past decade, Unjha Formulations' PEG Ratio has ranged from 0.69 to 26.36. According to the industry distribution chart, Unjha Formulations ranks #74 out of 351 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Unjha Formulations' PEG Ratio too high?
Unjha Formulations' current PEG Ratio of 0.78 is 58% below median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 26.36. The Drug Manufacturers industry median PEG Ratio is 1.72. Unjha Formulations' value of 0.78 is 54.7% below this industry median. Based on the distribution chart, Unjha Formulations ranks #74 out of 351 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Unjha Formulations has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #74 out of 351 companies for PEG Ratio. This places Unjha Formulations in the top 21% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.72. Unjha Formulations' value of 0.78 is 54.7% below this benchmark. Historically, Unjha Formulations' own PEG Ratio has ranged from 0.69 to 26.36 over the past decade. While the company's 10-year median is 1.85 vs. the industry median of 1.72, Unjha Formulations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 351 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current PEG Ratio of 0.78 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current PEG Ratio is 0.78, which is 58% below median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹23.17, compared to a current price of ₹26.01 — trading 12.3% above its estimated fair value. The current PEG Ratio is 0.78, which is 58% below median its 10-year median of 1.85 and 54.7% below the Drug Manufacturers industry median of 1.72. Unjha Formulations' overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current PEG Ratio is 0.78 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹26.01 is trading 12.3% above its estimated GF Value™ of ₹23.17.
GuruFocus considers Unjha Formulations to be Modestly Overvalued.
Key valuation signals for BOM:531762:
PEG Ratio: 0.78 (58% below median its 10-year median of 1.85)
GF Value™: ₹23.17 vs. price of ₹26.01 (12.3% above fair value)
Industry Position: 54.7% below the Drug Manufacturers median (#74 of 351)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
72GF Score
Get the complete analysis for BOM:531762
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
